BIIB Biogen Inc. Common Stock
XNAS
252.73
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
BIIB
$252.73
—
Key stats
$252.73
- 52-Week Range
- $138.00 – $254.41
- YTD
- +42.13%
- IV Rank (30D)
- 82.45
- Straddle Price
- $25.90
- P/C Vol Ratio
- 16.26
- Market Cap
- $37.3B
- Open
- $250.35
- Day Range
- $248.46 – $253.98
- Volume
- 1,393,392
- Prev Close
- $252.26
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 0.67 |
| Cost of Equity (CAPM) | 8.29% (VRP-adj) |
| WACC | 8.03% |
| Volatility Risk Premium | +28.0pp (IV − HV30) |
| Effective Tax Rate | 15.5% |
| Rev. Growth (YoY, DCF input) | -6.3% |
| DCF Horizon | 12 years explicit + fade |
| Free Cash Flow (TTM) | $2.7B |
| Return on Equity (TTM) | 4.4% |
| Book / Price | 50.2% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 75.5% |
| FCF Margin (TTM) | 27.1% |
| Debt / Equity | 0.34 |
| Quality Score | 4/6 — high quality (12y DCF) |
| Market-Implied Growth | -0.8% (reverse-DCF on current price) |
| SMA 50 | $224.23 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $232.10 |
| Bollinger Width / SMA20 | 7.9% (drives anchor stability) |
| Net Debt | $2.9B |
| Market Cap | $37B |
Peers used for multiples: AMGN, APGE, EXEL, GILD, HALO, MRNA, NBIX, RGEN, RVMD, TECH
(SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
76%
20-Day Fair Value
≈ by Nov 25, 2026
$257.72
α +2.0%
rank 61%
conviction
89%
40-Day Fair Value
≈ by Dec 24, 2026
$261.33
α +3.4%
rank 50%
conviction
91%
60-Day Fair Value
≈ by Jan 22, 2027
$259.57
α +2.7%
rank 46%
conviction
76%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $169.15 | 19% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $286.63 | 5% | median 30.8× · 6 peers |
| Peer EV/EBITDA | $305.47 | 6% | median 17.4× · 7 peers |
| Peer P/B | $1297.04 | 7% | median 10.2× · 10 peers |
| Peer P/S | $510.28 | 7% | median 7.6× · 8 peers |
| Market Anchor (SMA50) | $224.23 | 38% | stability 100% (BB-width) |
| Options Expected (B-L 30d) | $253.72 | 19% | 39 strikes · skew +0.14 |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $37.3B
- Employees
- 7,500
- List Date
- 1991-09-17
- CIK
- 0000875045
- Next Earnings
- 2026-10-28 (Pre-Market)
- EPS Forecast
- $2.05 (10 est.)
- Headquarters
- Cambridge, MA
- Homepage
- https://www.biogen.com
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eis…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 16.32% | -7.43% | 6.70% | -7.86% | -4.05% | 1.16% | 0.81% |
| Feb | -2.00% | -8.00% | -7.46% | -12.44% | -1.29% | 7.11% | -4.01% |
| Mar | 2.38% | 0.12% | 2.14% | -2.41% | -3.44% | -2.51% | -0.62% |
| Apr | -4.08% | -1.52% | 9.70% | -0.00% | -8.29% | 2.99% | -0.20% |
| May | -2.84% | -3.53% | -4.73% | 4.08% | 7.33% | 4.78% | 0.85% |
| Jun | 29.62% | 1.97% | -5.81% | 0.88% | -4.23% | 12.40% | 5.80% |
| Jul | -6.36% | 2.10% | -5.34% | -8.01% | -1.59% | -3.84% | -3.84% |
| Aug | 2.17% | -6.63% | -0.72% | -2.82% | 0.20% | 7.35% | -0.08% |
| Sep | -16.33% | 33.64% | -3.80% | -5.37% | 0.32% | 4.55% | 2.17% |
| Oct | -6.08% | 7.24% | -6.06% | -8.81% | 0.03% | 13.42%* | -0.04% |
| Nov | -13.36% | 8.97% | -2.31% | -7.57% | 20.24% | -- | 1.19% |
| Dec | 4.54% | -8.26% | 10.28% | -6.89% | -1.01% | -- | -0.27% |
| Total | -4.00% | 12.82% | -9.16% | -45.12% | 1.54% | 56.84% | 2.15% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $233.38
SMA 50: $225.10
SMA 200: $200.11
Current: $252.73
EMA 12: $242.26
EMA 26: $234.20
MACD: 8.0560 | Signal: 2.1939
BULLISH
ADX (14): 32.93
TREND
+DI: 36.51
−DI: 11.94
Momentum Oscillators
RSI (14): 71.80
OVERBOUGHT
Stoch %K: 93.49
Stoch %D: 93.34
Williams %R: -4.34
Volume & Volatility
BB Upper: $256.21
BB Lower: $210.55
NEUTRAL
OBV: 23,530,856
Vol SMA 20: 1,300,772
Vol ROC: 32.79%
ATR: $6.71
True Range: $5.52
HV 20: 30.3%
HV 30: 27.1%
HV 60: 27.4%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-29T00:00:00 – 2026-10-27T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall assessment: NEUTRAL with confidence level (6/10)
Key drivers:
- Recent positive news headlines
- Strong technical signals, including a bullish MACD crossover
- Low volatility and beta indicating a relatively stable stock
Primary risks:
- Potential for mean reversion or consolidation after recent gains
- Dependence on the biotech sector's performance
Investment thesis: Biogen's stock has been trending upward due to positive news headlines and technical signals. However, there is a risk of mean reversion or consolidation in the near term.
Recent news sentiment impact: The positive news headlines have contributed to the stock's recent gains.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Uptrend
- Medium-term (1-3 months): Uptrend
- Long-term (3-12 months): Neutral
Support/Resistance Levels:
- Upper Bollinger Band: $212.51
- Middle line: $203.54
- Lower Bollinger Band: $194.57
Momentum Signals: RSI interpretation: 52.03 (neutral) MACD signal: Bullish crossover above the signal line Bollinger Bands position: Neutral, with price between the upper and middle bands
Volume Analysis:
- Volume SMA 20: 1204766.40
- On-Balance Volume (OBV): 2005408.16
- Volume Rate of Change: -49.12%
News & Sentiment Analysis
Recent Headlines Summary: The recent news headlines have been generally positive, with articles highlighting Biogen's acquisition and partnerships.
Sentiment Assessment: Positive sentiment dominates the news headlines, contributing to the stock's upward trend.
Catalyst Identification: No specific catalysts identified in the near term, but the biotech sector's performance could impact the stock.
Market Narrative: The recent news has aligned with the technical signals, reinforcing the uptrend. However, there is a risk of mean reversion or consolidation if the market turns negative.
Risk & Volatility Assessment
Beta Interpretation: Beta of 0.25 indicates low volatility and a relatively stable stock.
Volatility Regime: Current volatility levels are low compared to historical norms.
Options Market Signals: IV rank: 3.7% (Low) Put/Call Volume Ratio: 1.00 (Neutral sentiment)
Downside Protection: Support levels include the middle and lower Bollinger Bands, with the potential for a mean reversion or consolidation in the near term.
Market Context & Positioning
Sector Performance: Biogen is performing relatively well within the biotech sector.
Institutional Activity: No specific institutional activity signals identified.
Correlation Analysis: The stock moves less than the market (beta <1), indicating a relatively stable asset.
Relative Valuation: The stock is positioned within its trading range, with potential for mean reversion or consolidation in the near term.
Key Levels & Action Items
Critical Price Levels:
- Upper Bollinger Band: $212.51
- Middle line: $203.54
- Lower Bollinger Band: $194.57
Breakout/Breakdown Levels: No specific levels identified, but mean reversion or consolidation could occur if the market turns negative.
Time-Sensitive Catalysts: No specific catalysts identified in the near term, but earnings data could impact the stock's performance.
Risk Management: Stop-loss levels and position sizing considerations should be implemented based on individual risk tolerance.
Generated
News
All BIIB news →
JPMorgan strongly reset its price target on the company's attractive 2027 pipeline catalysts.
Showing 1–10 of 11
Page 1 of 2
Earnings History
18 of 23 under expected move
Avg Expected Move
5.01%
Avg Actual Move
3.25%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-03 | Pre-Market | 5.22% | 5.21% | 1.00x | Within |
| 2021-04-22 | Pre-Market | 4.19% | 4.02% | 0.96x | Within |
| 2021-07-22 | Pre-Market | 5.20% | 1.05% | 0.20x | Within |
| 2021-10-20 | Pre-Market | 4.66% | 0.58% | 0.12x | Within |
| 2022-02-03 | Pre-Market | 5.45% | 2.13% | 0.39x | Within |
| 2022-05-03 | Pre-Market | 5.72% | 0.78% | 0.14x | Within |
| 2022-07-20 | Pre-Market | 3.88% | 5.80% | 1.49x | Exceeded |
| 2022-10-25 | Pre-Market | 5.19% | 0.39% | 0.08x | Within |
| 2023-02-15 | Pre-Market | 3.71% | 3.49% | 0.94x | Within |
| 2023-04-25 | Pre-Market | 4.33% | 3.62% | 0.84x | Within |
| 2023-07-25 | Pre-Market | 4.01% | 2.42% | 0.60x | Within |
| 2023-11-08 | Pre-Market | 5.21% | 5.67% | 1.09x | Exceeded |
| 2024-02-13 | Pre-Market | 5.60% | 7.39% | 1.32x | Exceeded |
| 2024-04-24 | Pre-Market | 5.93% | 4.56% | 0.77x | Within |
| 2024-08-01 | Pre-Market | 5.39% | 1.17% | 0.22x | Within |
| 2024-10-30 | Pre-Market | 5.86% | 1.25% | 0.21x | Within |
| 2025-02-12 | Pre-Market | 5.78% | 4.28% | 0.74x | Within |
| 2025-05-01 | Pre-Market | 5.33% | 0.12% | 0.02x | Within |
| 2025-07-07 | unknown | 4.00% | 3.33% | 0.83x | Within |
| 2025-10-30 | Pre-Market | 6.02% | 1.18% | 0.20x | Within |
| 2026-02-06 | Pre-Market | 4.94% | 8.53% | 1.73x | Exceeded |
| 2026-04-29 | Pre-Market | 4.80% | 6.00% | 1.25x | Exceeded |
| 2026-07-29 | Pre-Market | 4.91% | 1.76% | 0.36x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
BIIB Options Activity & IV Rank
BIIB IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 43.7%
7-DTE IV: 58.2%
Expected Move: $25.90
7-DTE Move: $18.15
Days to Exp: 31 (2026-11-27)
Options Flow
Call Volume: 23
Put Volume: 374
P/C Volume: 16.261
BEARISH
Call OI: 21
Put OI: 187
P/C OI: 8.905
Total OI: 208
ATM Options Pricing
ATM Call: $12.35
ATM Put: $13.55
Call %: 4.9%
Put %: 5.4%
Chain Summary
Chain Volume: 8,462
Chain OI: 50,440
Last Updated: 10/27/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 55th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
55%
vs own history
GEX tilt
+0.27
OI-weighted, today
Vanna tilt
+0.13
δ-sensitivity to IV
Charm tilt
-0.50
δ-decay vs time
Charm tilt -0.50: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 99 ATM contracts, 18k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
79%
+13.1
pts
EXTREME
ATM 48.5% / Wing 61.6%
30 DTE / 10d
72%
+9.3
pts
EXTREME
ATM 43.6% / Wing 52.9%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)81.7HighOct 27
IV Rank (30 DTE)82.5HighOct 27
Straddle Price (30 DTE)$25.90Oct 27
Beta Analysis
Risk Metrics
Beta: 0.2677
Alpha: 54.52%
Correlation: 0.1002
R-Squared: 1.0%
Stock Volatility: 34.0%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own BIIB
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $90.4M | #443 of 6285 | +203.0% | 13F | |
| Point72 Hedge fund Steve Cohen | $19.0M | #598 of 1945 | -89.1% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $16.8M | #787 of 3138 | -61.8% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $1.3M | #1568 of 4729 | -9.4% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
BIIB Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 147,325,000 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
34 filers$693.87M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $136.18M | 19.63% | 2026-06-30 |
| 2 | UBS Group AG Custodian | $108.29M | 15.61% | 2026-06-30 |
| 3 | LMR Partners LLP | $84.05M | 12.11% | 2026-06-30 |
| 4 | Citadel Advisors LLC Custodian | $68.06M | 9.81% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $41.29M | 5.95% | 2026-06-30 |
| 6 | Patient Capital Management, LLC | $40.92M | 5.90% | 2026-06-30 |
| 7 | IMC-Chicago, LLC Custodian | $28.07M | 4.04% | 2026-06-30 |
| 8 | Balyasny Asset Management L.P. | $21.61M | 3.11% | 2026-06-30 |
| 9 | SPHERA FUNDS MANAGEMENT LTD. | $21.61M | 3.11% | 2026-06-30 |
| 10 | PEAK6 LLC | $20.37M | 2.94% | 2026-06-30 |
| 11 | Wolverine Trading, LLC Custodian | $17.95M | 2.59% | 2025-09-30 |
| 12 | Citigroup Inc. Custodian | $16.49M | 2.38% | 2026-06-30 |
| 13 | Simplex Trading, LLC Custodian | $15.28M | 2.20% | 2026-06-30 |
| 14 | DIADEMA PARTNERS LP | $12.96M | 1.87% | 2026-06-30 |
| 15 | GROUP ONE TRADING LLC Custodian | $12.32M | 1.77% | 2026-06-30 |
| 16 | DLD Asset Management, LP | $8.10M | 1.17% | 2026-06-30 |
| 17 | Walleye Trading LLC | $6.78M | 0.98% | 2026-06-30 |
| 18 | NOMURA HOLDINGS INC | $4.99M | 0.72% | 2026-06-30 |
| 19 | Goldman Sachs Group Inc Custodian | $4.32M | 0.62% | 2026-06-30 |
| 20 | Vontobel Holding Ltd. | $3.48M | 0.50% | 2026-09-30 |
| 21 | Millennium Management LLC Custodian | $3.18M | 0.46% | 2026-06-30 |
| 22 | Caption Management, LLC | $2.96M | 0.43% | 2026-06-30 |
| 23 | Cubist Systematic Strategies, LLC | $2.94M | 0.42% | 2025-09-30 |
| 24 | Maven Securities LTD | $2.64M | 0.38% | 2026-06-30 |
| 25 | Walleye Capital LLC | $2.59M | 0.37% | 2026-06-30 |
30 filers$480.95M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $204.35M | 42.49% | 2026-06-30 |
| 2 | LMR Partners LLP | $62.27M | 12.95% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $47.12M | 9.80% | 2026-06-30 |
| 4 | Barclays PLC Custodian | $38.89M | 8.09% | 2026-06-30 |
| 5 | Citadel Advisors LLC Custodian | $29.00M | 6.03% | 2026-06-30 |
| 6 | IMC-Chicago, LLC Custodian | $25.34M | 5.27% | 2026-06-30 |
| 7 | Caption Management, LLC | $10.80M | 2.25% | 2026-06-30 |
| 8 | NOMURA HOLDINGS INC | $9.23M | 1.92% | 2026-06-30 |
| 9 | Millennium Management LLC Custodian | $7.52M | 1.56% | 2026-06-30 |
| 10 | Walleye Trading LLC | $7.22M | 1.50% | 2026-06-30 |
| 11 | Wolverine Trading, LLC Custodian | $6.08M | 1.26% | 2025-09-30 |
| 12 | GROUP ONE TRADING LLC Custodian | $4.90M | 1.02% | 2026-06-30 |
| 13 | Goldman Sachs Group Inc Custodian | $4.32M | 0.90% | 2026-06-30 |
| 14 | Squarepoint Ops LLC | $3.93M | 0.82% | 2026-06-30 |
| 15 | Simplex Trading, LLC Custodian | $3.39M | 0.71% | 2026-06-30 |
| 16 | Walleye Capital LLC | $2.70M | 0.56% | 2026-06-30 |
| 17 | J. Goldman & Co LP | $2.61M | 0.54% | 2026-06-30 |
| 18 | PEAK6 LLC | $1.73M | 0.36% | 2026-06-30 |
| 19 | HSBC Holdings plc Custodian | $1.73M | 0.36% | 2026-06-30 |
| 20 | Cubist Systematic Strategies, LLC | $1.60M | 0.33% | 2025-09-30 |
| 21 | D. E. Shaw & Co., Inc. Custodian | $1.38M | 0.29% | 2026-06-30 |
| 22 | Baader Bank Aktiengesellschaft | $907.45K | 0.19% | 2026-06-30 |
| 23 | Vontobel Holding Ltd. | $903.52K | 0.19% | 2026-09-30 |
| 24 | Qube Research & Technologies Ltd | $799.42K | 0.17% | 2026-06-30 |
| 25 | Marshall Wace, LLP Custodian | $540.15K | 0.11% | 2026-06-30 |
BIIB Insider Trading (Form 4)
Latest: 2026-10-05Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Sean Godbout | Chief Accounting Officer | Mixed | +19 | $219.88 | -$1.8K | EDGAR |
| 2026-09-03 | Michael Parini | Chief Legal Officer | Grant (A) | +7,405 RSU | — | EDGAR | |
| 2026-08-05 | Lloyd Minor | Director | Sell (S) | −1,186 | $202.15 | -$239.7K | EDGAR |
| 2026-06-11 | Maria C Freire | Director | Award (A) | +2,005 | — | EDGAR | |
| 2026-06-11 | Eric K Rowinsky | Director | Award (A) | +1,505 | — | EDGAR | |
| 2026-06-11 | Lloyd Minor | Director | Award (A) | +1,505 | — | EDGAR | |
| 2026-06-11 | Monish D Patolawala | Director | Award (A) | +1,505 | — | EDGAR | |
| 2026-06-11 | Jesus B Mantas | Director | Award (A) | +1,505 | — | EDGAR | |
| 2026-06-11 | William A Hawkins | Director | Award (A) | +1,505 | — | EDGAR | |
| 2026-06-11 | Stephen A Sherwin | Director | Award (A) | +1,505 | — | EDGAR | |
| 2026-06-11 | Susan Langer | Director | Award (A) | +1,505 | — | EDGAR | |
| 2026-06-11 | Menelas N Pangalos | Director | Mixed | +3,875 | — | EDGAR | |
| 2026-05-05 | Adam Keeney | Head of Corporate Development | Mixed | +484 | $187.06 | -$85.1K | EDGAR |
| 2026-04-03 | Sean Godbout | Chief Accounting Officer | Mixed | +127 | $183.78 | -$9.9K | EDGAR |
| 2026-02-17 | Susan H Alexander | EVP Chief Legal Officer | Grant (A) | +8,450 RSU | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
BIIB Insider Holdings
21 insiders · @ $252.73
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Susan H Alexander | EVP Chief Legal Officer | 63,403 | $16.02M | -$30.25M | 80 | 2026-02-17 |
| 2 | Caroline Dorsa | Director | 31,002 | $7.84M | -$11.91M | 27 | 2025-06-18 |
| 3 | Eric K Rowinsky | Director | 25,844 | $6.53M | -$12.52M | 24 | 2026-06-11 |
| 4 | Michael R. McDonnell | EVP, Chief Financial Officer | 25,712 | $6.50M | $0 | 16 | 2025-02-12 |
| 5 | Christopher Viehbacher | President and CEO | 25,451 | $6.43M | $0 | 6 | 2026-02-17 |
| 6 | Ginger Gregory | EVP, Human Resources | 22,358 | $5.65M | -$2.49M | 28 | 2026-02-17 |
| 7 | Nicole Murphy | Head of Pharm Ops and Tech | 19,611 | $4.96M | $585 | 20 | 2026-02-17 |
| 8 | Stephen A Sherwin | Director | 15,193 | $3.84M | -$10.17M | 30 | 2026-06-11 |
| 9 | Jesus B Mantas | Director | 11,263 | $2.85M | $239.8K | 9 | 2026-06-11 |
| 10 | William A Hawkins | Director | 10,365 | $2.62M | $0 | 8 | 2026-06-11 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
BIIB Board & Officers
As of SEC filings through Oct 5, 2026Directors 10
- Eric K Rowinsky · since Mar 20, 2010
- Stephen A Sherwin · since Mar 20, 2010
- Jesus B Mantas · since Jun 19, 2019
- William A Hawkins · since Jun 19, 2019
- Maria C Freire · since Jun 2, 2021
- Christopher Viehbacher · since Nov 14, 2022
- Susan Langer · since Jun 26, 2023
- Monish D Patolawala · since Jan 1, 2024
- Lloyd Minor · since Oct 1, 2024
- Menelas N Pangalos · since Jan 1, 2025
Officers 10
- Christopher Viehbacher · President and CEO · since Nov 14, 2022
- Robin Kramer · Chief Financial Officer · listed since Feb 2026
- Sean Godbout · Chief Accounting Officer · since Mar 1, 2025
- Michael Parini · Chief Legal Officer · since Aug 3, 2026
- Ginger Gregory · EVP, Human Resources · since Jul 17, 2017
- Nicole Murphy · Head of Pharm Ops and Tech · since Feb 7, 2022
- Priya Singhal · Head of Development · since Jan 5, 2023
- Rachid Izzar · Head of Global Product Strat. · listed since Feb 2023
- Adam Keeney · Head of Corporate Development · since Apr 17, 2023
- Jane Grogan · Head of Research · since Oct 2, 2023
Changes in the last 10 years (48)
| Aug 3, 2026 | Michael Parini became Chief Legal Officer |
| Mar 11, 2026 | The company announced the departure of Susan H Alexander as EVP Chief Legal Officer in an SEC filing |
| Feb 11, 2026 | The company announced the departure of Caroline Dorsa from the board in an SEC filing |
| Feb 10, 2026 | Robin Kramer listed as Chief Financial Officer (previously Chief Accounting Officer) in SEC filings |
| Mar 1, 2025 | Sean Godbout became Chief Accounting Officer |
| Jan 1, 2025 | Menelas N Pangalos became a director |
| Oct 28, 2024 | The company announced the departure of Michael R McDonnell as EVP, Chief Financial Officer in an SEC filing |
| Oct 1, 2024 | Lloyd Minor became a director |
| Jan 31, 2024 | Susan H Alexander listed as EVP Chief Legal Officer (previously EVP Chief Legal Off & Corp Sec) in SEC filings |
| Jan 1, 2024 | Monish D Patolawala became a director |
| Oct 2, 2023 | Jane Grogan became Head of Research |
| Jun 26, 2023 | Susan Langer became a director |
| Apr 17, 2023 | Adam Keeney became Head of Corporate Development |
| Mar 5, 2023 | The company announced the departure of Stelios Papadopoulos from the board in an SEC filing |
| Feb 10, 2023 | Rachid Izzar listed as Head of Global Product Strat. (previously Head of Alzheimer's Disease) in SEC filings |
| Jan 27, 2023 | Brian S Posner reported in an SEC filing no longer being a director |
| Jan 5, 2023 | Priya Singhal became Head of Development |
| Nov 14, 2022 | Christopher Viehbacher became a director |
| Nov 14, 2022 | Christopher Viehbacher became President and CEO |
| Nov 10, 2022 | The company announced the departure of Michel Vounatsos from the board in an SEC filing |
| May 3, 2022 | The company announced the departure of Michel Vounatsos as Chief Executive Officer in an SEC filing |
| Feb 7, 2022 | Nicole Murphy became Head of Pharm Ops and Tech |
| Jan 25, 2022 | The company announced the departure of Nancy Leaming from the board in an SEC filing |
| Nov 15, 2021 | The company announced the departure of Alfred Sandrock as EVP, Research & Development in an SEC filing |
| Jul 22, 2021 | Rachid Izzar became Head of Alzheimer's Disease |
| Jul 2, 2021 | Robin Kramer listed as Chief Accounting Officer (previously SVP, Chief Accounting Officer) in SEC filings |
| Jun 9, 2021 | Chirfi Guindo listed as Head of Glob Prod Strat & Com (previously EVP Glob. Prod Strat and Comm) in SEC filings |
| Jun 2, 2021 | William D /ca/ Jones became a director |
| Jun 2, 2021 | Maria C Freire became a director |
| Feb 17, 2021 | Robin Kramer listed as SVP, Chief Accounting Officer (previously VP, Chief Accounting Officer) in SEC filings |
| Aug 15, 2020 | Michael R McDonnell became EVP, Chief Financial Officer |
| Feb 14, 2020 | Susan H Alexander listed as EVP Chief Legal Off & Corp Sec (previously EVP Chief Legal Officer & Sec.) in SEC filings |
| Feb 14, 2020 | Alfred Sandrock listed as EVP, Research & Development (previously EVP, Chief Medical Officer) in SEC filings |
| Dec 3, 2019 | Chirfi Guindo listed as EVP Glob. Prod Strat and Comm (previously EVP Glob. Mkt Acc & Cust Innov) in SEC filings |
| Sep 19, 2019 | Alphonse Galdes became EVP Pharmaceutical Oper & Tech |
| Jun 19, 2019 | William A Hawkins became a director |
| Jun 19, 2019 | Jesus B Mantas became a director |
| Feb 14, 2019 | Susan H Alexander listed as EVP Chief Legal Officer & Sec. (previously EVP Chief Legal Corp Svc & Sec) in SEC filings |
| Nov 19, 2018 | Robin Kramer became VP, Chief Accounting Officer |
| Jun 11, 2018 | Daniel Karp became EVP, Corporate Development |
| Feb 14, 2018 | Alfred Sandrock listed as EVP, Chief Medical Officer (previously EVP CMO Neuro & Neurodegenerat) in SEC filings |
| Dec 11, 2017 | Jeffrey D Capello became EVP & Chief Financial Officer |
| Nov 7, 2017 | Chirfi Guindo became EVP Glob. Mkt Acc & Cust Innov |
| Jul 20, 2017 | Susan H Alexander listed as EVP Chief Legal Corp Svc & Sec (previously EVP, Chief Legal Officer) in SEC filings |
| Jul 17, 2017 | Ginger Gregory became EVP, Human Resources |
| Jun 14, 2017 | Jean-Paul Kress became EVP Pres Int'l & Global Hd GTO |
| Feb 17, 2017 | Michel Vounatsos listed as Chief Executive Officer (previously EVP & Chief Commercial Officer) in SEC filings |
| Feb 17, 2017 | Michel Vounatsos first listed as a director in an SEC filing |
Not reported recently (16)
- Richard Mulligan · Last reported as a director in an SEC filing dated Jun 17, 2022
- Alexander J Denner · Last reported as a director in an SEC filing dated Jun 17, 2022
- William D /ca/ Jones · Last reported as a director in an SEC filing dated Jun 17, 2022
- Chirfi Guindo · Last reported as Head of Glob Prod Strat & Com in an SEC filing dated Feb 23, 2022
- Alphonse Galdes · Last reported as EVP Pharmaceutical Oper & Tech in an SEC filing dated Jan 21, 2022
- Robert W Pangia · Last reported as a director in an SEC filing dated Feb 9, 2021
- Jeffrey D Capello · Last reported as EVP & Chief Financial Officer in an SEC filing dated Feb 14, 2020
- Daniel Karp · Last reported as EVP, Corporate Development in an SEC filing dated Feb 14, 2020
- Lynn Schenk · Last reported as a director in an SEC filing dated Jun 20, 2019
- Michael D Ehlers · Last reported as EVP, Research and Development in an SEC filing dated Jun 4, 2019
- Paul McKenzie · Last reported as EVP Pharmaceutical Oper & Tech in an SEC filing dated Mar 5, 2019
- Gregory F Covino · Last reported as VP, Chief Accounting Officer in an SEC filing dated Mar 5, 2018
- Jean-Paul Kress · Last reported as EVP Pres Int'l & Global Hd GTO in an SEC filing dated Jul 5, 2017
- Paul J Clancy · Last reported as Executive VP and CFO in an SEC filing dated Apr 27, 2017
- Kenneth DiPietro · Last reported as EVP Human Resources in an SEC filing dated Mar 2, 2017
- Adriana Karaboutis · Last reported as EVP, Tech, Bus. Sol & Corp Aff in an SEC filing dated Mar 2, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
BIIB Proposed Insider Sales (Form 144)
Latest: 2026-08-04
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
2 filings
· $240K notice value
· 1 unique filer
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Minor Lloyd (2, $240K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Minor Lloyd | Director | 593 | $119.2K | 2026-08-04 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-08-03 | Minor Lloyd | Director | 593 | $120.6K | 2026-08-03 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-02-09 | Singhal Priya | Officer | 2,660 | $531.5K | 2026-02-09 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-02-02 | Singhal Priya | Officer | 748 | $134.1K | 2026-02-02 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2025-09-02 | Singhal Priya | Officer | 517 | $69.0K | 2025-09-02 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2025-07-08 | Izzar Rachid | Officer | 2,223 | $300.1K | 2025-07-08 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2025-05-19 | Singhal Priya | Officer | 3,806 | $480.5K | 2025-05-19 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2025-03-07 | STEPHEN A SHERWIN | Director | 8,760 | $1.29M | 2025-03-07 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2024-12-09 | Singhal Priya | Officer | 110 | $17.3K | 2024-12-09 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2024-09-03 | Singhal Priya | Officer | 431 | $88.0K | 2024-09-03 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-05-14
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-14 | 0001193125-26-222908 | EDGAR |
| 2026-04-29 | 0000875045-26-000042 | EDGAR |
| 2026-04-06 | 0000875045-26-000039 | EDGAR |
| 2026-03-31 | 0001193125-26-134889 | EDGAR |
| 2026-03-11 | 0000950157-26-000280 | EDGAR |
| 2026-02-11 | 0001193125-26-046803 | EDGAR |
| 2026-02-06 | 0000875045-26-000011 | EDGAR |
| 2026-01-14 | 0000875045-26-000003 | EDGAR |
| 2025-10-30 | 0000875045-25-000047 | EDGAR |
| 2025-10-14 | 0000875045-25-000040 | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-02-06 | 0000875045-26-000013 | EDGAR |
| 2025-02-12 | 0000875045-25-000009 | EDGAR |
| 2024-02-14 | 0000875045-24-000009 | EDGAR |
| 2023-02-15 | 0000875045-23-000009 | EDGAR |
| 2022-02-03 | 0000875045-22-000007 | EDGAR |
| 2021-02-03 | 0000875045-21-000010 | EDGAR |
| 2020-02-06 | 0000875045-20-000005 | EDGAR |
| 2019-02-06 | 0000875045-19-000006 | EDGAR |
| 2018-02-01 | 0000875045-18-000005 | EDGAR |
| 2017-02-02 | 0000875045-17-000009 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-04-29 | 0000875045-26-000045 | EDGAR |
| 2025-10-30 | 0000875045-25-000049 | EDGAR |
| 2025-07-31 | 0000875045-25-000033 | EDGAR |
| 2025-05-01 | 0000875045-25-000018 | EDGAR |
| 2024-10-30 | 0000875045-24-000032 | EDGAR |
| 2024-08-01 | 0000875045-24-000025 | EDGAR |
| 2024-04-24 | 0000875045-24-000016 | EDGAR |
| 2023-11-08 | 0000875045-23-000038 | EDGAR |
| 2023-07-25 | 0000875045-23-000030 | EDGAR |
| 2023-04-25 | 0000875045-23-000016 | EDGAR |
ETF Holders
317 ETFs hold BIIB
25 shown · $6.19B total exposure · 0.11% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.05% | $1.1B | — | 2026-09-30 |
| 2 | VOO Vanguard S&P 500 ETF | Vanguard | 0.05% | $876.8M | — | 2026-09-30 |
| 3 | VO Vanguard Morningstar Mid-Cap ETF | Vanguard | 0.33% | $714.7M | — | 2026-09-30 |
| 4 | IVV iShares Core S&P 500 ETF | iShares (BlackRock) | 0.06% | $492.8M | $880.6B | 2026-10-23 |
| 5 | SPY State Street® SPDR® S&P 500® ETF Trust | SPDR (State Street) | 0.06% | $456.8M | $807.9B | 2026-10-23 |
| 6 | VTV Vanguard Morningstar Value ETF | Vanguard | 0.13% | $317.9M | — | 2026-09-30 |
| 7 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 2.62% | $279.8M | $10.7B | 2026-10-23 |
| 8 | XLV State Street® Health Care Select Sector SPDR® ETF | SPDR (State Street) | 0.57% | $267.4M | $47.0B | 2026-10-23 |
| 9 | RSP Invesco S&P 500 Equal Weight ETF | Invesco | 0.24% | $233.7M | — | 2026-10-24 |
| 10 | VOE Vanguard Morningstar Mid-Cap Value ETF | Vanguard | 0.57% | $208.4M | — | 2026-09-30 |
| 11 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 1.80% | $186.5M | $10.4B | 2026-10-23 |
| 12 | IWR iShares Russell Mid-Cap ETF | iShares (BlackRock) | 0.27% | $154.9M | $57.3B | 2026-10-23 |
| 13 | COWZ Pacer US Cash Cows 100 ETF | Nport | 0.72% | $134.7M | — | 2026-07-31 |
| 14 | FBT First Trust NYSE® Arca® Biotechnology Index Fund | First Trust | 3.65% | $108.8M | $3.0B | 2026-10-23 |
| 15 | SPYM State Street® SPDR® Portfolio S&P 500® ETF | SPDR (State Street) | 0.06% | $102.4M | $181.7B | 2026-10-23 |
| 16 | VHT Vanguard Health Care ETF | Vanguard | 0.47% | $101.9M | — | 2026-09-30 |
| 17 | IWD iShares Russell 1000 Value ETF | iShares (BlackRock) | 0.10% | $82.8M | $84.8B | 2026-10-23 |
| 18 | CALF Pacer US Small Cap Cash Cows 100 ETF | Nport | 1.91% | $70.2M | — | 2026-07-31 |
| 19 | IVE iShares S&P 500 Value ETF | iShares (BlackRock) | 0.12% | $61.6M | $50.6B | 2026-10-23 |
| 20 | IWS iShares Russell Mid-Cap Value ETF | iShares (BlackRock) | 0.36% | $56.2M | $15.7B | 2026-10-23 |
| 21 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.05% | $48.1M | $96.5B | 2026-10-23 |
| 22 | SPYV State Street® SPDR® Portfolio S&P 500® Value ETF | SPDR (State Street) | 0.12% | $47.2M | $38.6B | 2026-10-23 |
| 23 | FTXH First Trust Nasdaq Pharmaceuticals ETF | First Trust | 4.02% | $45.9M | $1.1B | 2026-10-23 |
| 24 | GSLC Goldman Sachs ActiveBeta U.S. Large Cap Equity ETF | Goldman | 0.29% | $43.8M | $15.1B | 2026-10-23 |
| 25 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.05% | $42.8M | — | 2026-10-23 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
27.18
TTM Diluted EPS
$9.30
TTM Revenue
$9.94B
TTM Net Income
$1.37B
TTM Op. Cash Flow
$2.60B
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | $2.48B | $319.50M | $2.15 | $645.50M |
| Q4 '25 | 2025-12-31 | $2.28B | $-48.90M | $-0.35 | $511.90M |
| Q3 '25 | 2025-09-30 | $2.53B | $466.50M | $3.17 | $1.27B |
| Q2 '25 | 2025-06-30 | $2.65B | $634.80M | $4.33 | $170.50M |
| Q1 '25 | 2025-03-31 | $2.43B | $240.50M | $1.64 | $259.30M |
| Q4 '24 | 2024-12-31 | $2.45B | $266.70M | $1.83 | $760.90M |
| Q3 '24 | 2024-09-30 | $2.47B | $388.50M | $2.66 | $935.60M |
| Q2 '24 | 2024-06-30 | $2.46B | $583.60M | $4.00 | $625.80M |
| Q1 '24 | 2024-03-31 | $2.29B | $393.40M | $2.70 | $553.20M |
| Q4 '23 | 2023-12-31 | $2.39B | $249.70M | $1.71 | $12.50M |
| Q3 '23 | 2023-09-30 | $2.53B | $-68.10M | $-0.47 | $592.40M |
| Q2 '23 | 2023-06-30 | $2.46B | $591.60M | $4.07 | $487.00M |
Q1 2026 • period ending 2026-03-31 • filed 2026-04-29
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
27.18
P/B
2.00
P/S
3.75
EV/EBITDA
14.62
EV/Sales
4.04
ROE
7.4%
ROA
4.7%
Div Yield
0.00%
FCF Yield
6.98%
Debt/Equity
0.34
Current Ratio
—
Market Cap
$37.23B
as of 2026-10-27
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
5.97M
SI % of Float
4.04%
Days to Cover
4.87
Short Vol Ratio
57.6%
Free Float
147.50M
Float %
99.8%
Short interest 2026-09-30 • Short volume 2026-10-27 • Float 2026-08-24